A Phase 1 interventional study of NMS-03305293 in Advanced/Metastatic Solid Tumors, sponsored by Nerviano Medical Sciences. Terminated at 10 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Nerviano Medical Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Phase I, first-in-human, open-label, multicenter, dose-escalation and dose expansion study with the aim of exploring safety, tolerability and preliminary antitumor activity of NMS-03305293 (a PARP inhibitor) as single agent in adult patients with selected advanced/metastatic, relapsed/refractory solid tumors who have exhausted standard treatment options or for whom standard therapy is considered unsuitable.
798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 102 are open to participants now.
This study's enrollment of 52 is above the median of 45 across 585 interventional studies indexed under Carcinoma, Ovarian Epithelial.
Browse Carcinoma, Ovarian Epithelial studies →Nerviano Medical Sciences is the lead sponsor of 15 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion Criteria for Dose Escalation and Dose Expansion Part:
Patients must have progressive disease defined by 1.1 following standard therapy or be unsuitable for standard therapy. For CRPC patients, disease progression at study entry is defined as one or more of the following three criteria (according to PCWG2):
Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study indications or procedures.
Inclusion Criteria specific for Dose Expansion Part:
Patients must have received the following previous treatment:
Exclusion Criteria:
Prior except for any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with histologically confirmed diagnosis of locally advanced/metastatic HER2 negative breast cancer, epithelial ovarian cancer, castration-resistant prostate cancer (CRPC) or pancreatic cancer.
Drug: NMS-03305293
Patients with gBRCA mutation and epithelial ovarian cancer.
Drug: NMS-03305293
Patients with gBRCA mutation and HER2 negative breast cancer previously treated with a PARP inhibitor.
Drug: NMS-03305293
Patients with gBRCA mutation and HER2 negative breast cancer who have not received prior therapy with a PARP inhibitor.
Drug: NMS-03305293
Patients with gBRCA mutation and castration-resistant prostate cancer (CRPC).
Drug: NMS-03305293
Patients with gBRCA mutation and pancreatic cancer who have not received prior therapy with a PARP inhibitor.
Drug: NMS-03305293
All patients will receive NMS-03305293 administered orally on Days 1-21 (schedule A) or Days 1-28 (schedule B) in repeated 4-week cycles.
Number of Participants with first-cycle dose limiting toxicity
Time frame: Time interval between the date of the first dose administration in Cycle 1 (each cycle is 28 days) and the date of the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to toxicity
Number of participants with Adverse Events (AEs)
Safety will be assessed by AEs, which includes clinically significant abnormalities identified during a medical test (e.g. laboratory tests, vital signs, electrocardiogram, etc.). A treatment-emergent AE is defined as an AE observed after starting administration of the study drug up to 28 days after last dose of study medication intake. AEs will be coded with Medical Dictionary for Regulatory Activities and graded according to The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.
Time frame: From the Informed Consent signature to 28 days after the last dose of study treatment administration.
Maximum concentration (Cmax) of NMS-03305293 after single and multiple doses of drug
Plasma samples will be collected and used for pharmacokinetics assessments.
Time frame: Full PK : Schedule A, QD and BID dosing: Cycle 1, 2; Schedule B, QD and BID dosing: Cycle 1, 2 and 3. Sparse PK: Schedule A: and Schedule B Cycle 1, 2, 3 (last cycle and at each cycle from cycle 1 onwards).Cycle lenght is 4 weeks.
Time to observed Cmax (Tmax) of NMS-033052293 after single and multiple doses of drug
Plasma samples will be collected and used for pharmacokinetics assessments.
Time frame: Full PK : Schedule A, QD and BID dosing: Cycle 1, 2; Schedule B, QD and BID dosing: Cycle 1, 2 and 3. Sparse PK: Schedule A: and Schedule B Cycle 1, 2, 3 (last cycle and at each cycle from cycle 1 onwards).Cycle lenght is 4 weeks.
Area under the concentration-time curve to the last of measurable concentration (AUClast) of NMS-033052293 after single and repeated dose of drug.
Plasma samples will be collected and used for pharmacokinetics assessments.
Time frame: Full PK : Schedule A, QD and BID dosing: Cycle 1, 2; Schedule B, QD and BID dosing: Cycle 1, 2 and 3. Sparse PK: Schedule A: and Schedule B Cycle 1, 2, 3 (last cycle and at each cycle from cycle 1 onwards).Cycle lenght is 4 weeks.
Terminal elimination half-life (t1/2) of NMS-033052293 after single and multiple doses of drug.
Plasma samples will be collected and used for pharmacokinetics assessments.
Time frame: Full PK : Schedule A, QD and BID dosing: Cycle 1, 2; Schedule B, QD and BID dosing: Cycle 1, 2 and 3. Sparse PK: Schedule A: and Schedule B Cycle 1, 2, 3 (last cycle and at each cycle from cycle 1 onwards).Cycle lenght is 4 weeks.
Area under the plasma concentration vs. time curve to infinity (AUCinf) of NMS-033052293 after multiple doses of drug.
Plasma samples will be collected and used for pharmacokinetics assessments.
Time frame: Full PK : Schedule A, QD and BID dosing: Cycle 1, 2; Schedule B, QD and BID dosing: Cycle 1, 2 and 3. Sparse PK: Schedule A: and Schedule B Cycle 1, 2, 3 (last cycle and at each cycle from cycle 1 onwards).Cycle lenght is 4 weeks.
Accumulation ratio (Rac) of NMS-033052293 after multiple doses of drug.
Plasma samples will be collected and used for pharmacokinetics assessments.
Time frame: Full PK : Schedule A, QD and BID dosing: Cycle 1, 2; Schedule B, QD and BID dosing: Cycle 1, 2 and 3. Sparse PK: Schedule A: and Schedule B Cycle 1, 2, 3 (last cycle and at each cycle from cycle 1 onwards).Cycle lenght is 4 weeks.
Oral plasma clearance (CL/F) of NMS-033052293 after multiple doses of drug.
Plasma samples will be collected and used for pharmacokinetics assessments.
Time frame: Full PK : Schedule A, QD and BID dosing: Cycle 1, 2; Schedule B, QD and BID dosing: Cycle 1, 2 and 3. Sparse PK: Schedule A: and Schedule B Cycle 1, 2, 3 (last cycle and at each cycle from cycle 1 onwards).Cycle lenght is 4 weeks.
Apparent volume of distribution (Vd/F) of NMS-033052293 after multiple doses of drug.
Plasma samples will be collected and used for pharmacokinetics assessments.
Time frame: Full PK : Schedule A, QD and BID dosing: Cycle 1, 2; Schedule B, QD and BID dosing: Cycle 1, 2 and 3. Sparse PK: Schedule A: and Schedule B Cycle 1, 2, 3 (last cycle and at each cycle from cycle 1 onwards).Cycle lenght is 4 weeks.
Renal clearance of NMS-033052293 after multiple doses of drug.
Samples of urine will be used for pharmacokinetics assessments. To be collected in all patients enrolled after the first DLT.
Time frame: Schedule A, QD and BID dosing: Cycle 1 (Day 1 and 21). ; Schedule B, QD and BID dosing: Cycle 1 (Day 1 and 28).Cycle lenght is 4 weeks.
Objective tumor response (OR)
Objective tumor response (OR) measured using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. For prostate cancer patients response will be evaluated by RECIST version 1.1/PCWG3 for patients with measurable disease and by Prostatic Specific Antigen (PSA) for all patients through PCWG3 criteria.
Time frame: At baseline, every even cycle (Day 28), at the end of treatment and at follow-up, every 8 weeks, till disease progression, an average 18 months.
Progression Free Survival (PFS)
Progression Free Survival (PFS) will be calculated from the date of treatment initiation to the date of first documentation of disease progression according to RECIST 1.1 or RECIST 1.1/PCWG3 for patient with CRPC, or death due to any cause, whichever comes first.
Time frame: From date of first dose of study drug up to the date of first documentation of disease progression or death due to any cause, whichever comes first, an average of 2 years.
Time To Progression (TTP)
Time to Progression (TTP) will be evaluated from the date of treatment initiation to the date of first documentation of disease progression according to RECIST 1.1 criteria or RECIST 1.1/PCWG3 for patient with CRPC, or death due to progression, whichever comes first.
Time frame: From date of first dose of study drug up to the date of first documentation of disease progression or death due to progression, an average of 2 years.
Time to PSA progression (for prostate cancer only)
Time to PSA Progression will be calculated from the date of treatment initiation to the date of first documentation of PSA progression according to PCWG3 criteria.
Time frame: From date of first dose of study drug up to the date of first documentation of PSA progression, an average of 1 year.
Ran from Nov 2019 to primary completion in Mar 2023, 40 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Itareparib
Carcinoma, Ovarian Epithelial →
Nerviano Medical Sciences